Sexually Transmitted Infections

A study presented at the Infectious Disease Society for Obstetrics and Gynecology 2024 Annual Meeting found an increase of 4 days between diagnosis and treatment among pregnant patients with congenital syphilis vs those without congenital syphilis.

A study presented at the Infectious Disease Society for Obstetrics and Gynecology 2024 Annual Meeting highlights the importance of affordability and convenience in boosting STI test uptake among adolescents and young adults.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Following evidence from recent studies, the Centers for Disease Control and Prevention has recommended the use of doxycycline postexposure prophylaxis in sexual health among certain populations.

A recent study highlights the necessity of optimizing secondary prevention strategies to mitigate adverse cardiovascular outcomes in patients with HIV who face higher risks.

Despite WHO’s goals to reduce syphilis and other STI infections by 2030, rising case numbers underscore the urgent need for intensified global disease prevention and control efforts.

Preventing congenital syphilis comes down to quick diagnosis and treatment of the infection in pregnancy, and the number of missed opportunities to do so in the United States continues to grow.

Explore the latest findings revealing vaccination rates among children aged 9 to 17 years, uncovering demographic disparities and highlighting the crucial role of vaccination in combating human papillomavirus infections and related health risks.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Dive into the rising prevalence of sexually transmitted infections among adolescents and young adults, exploring educational gaps, vaccination rates, and the imperative need for open conversations between patients and health care providers to combat stigma and enhance preventive care.

Discover the findings from a recent study highlighting the need to enhance vaccination rates among pregnant individuals living with HIV, shedding light on key factors influencing vaccine receipt.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

In a recent interview, Cheruba Prabakar, MD, FACOG, shed light on the rising prevalence of sexually transmitted infections in the United States and the need for improved awareness and testing, particularly for overlooked conditions such as trichomoniasis.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

Research presented at the 2024 Conference on Retroviruses and Opportunistic Infections reveals that long-acting injectable antiretroviral therapy provides improved HIV suppression with minimal adverse effects, offering a promising alternative for adolescents and individuals struggling with daily oral regimens.

Research presented at the 2024 Conference on Retroviruses and Opportunistic Infections reveals that 4 children, treated with antiretroviral therapy within 48 hours of birth, have achieved over a year of HIV remission.

A recent study assessed the effectiveness of GeneXpert point-of-care testing in detecting chlamydia, gonorrhoea, and trichomonas, revealing promising results but highlighting concerns over sensitivity rates, particularly for trichomonas.

Recent findings affirm the safety of monthly dapivirine vaginal rings and daily oral PrEP with tenofovir disoproxil fumarate and emtricitabine in preventing HIV transmission among pregnant cisgender women.

A recent study revealed the effectiveness of the AI tool MySTIRisk in pinpointing high-risk subgroups for HIV and other sexually transmitted infections, shedding light on improved risk assessment and testing accessibility.

Discover how the REPRIEVE trial sheds light on the increased cardiovascular risk among HIV patients, urging updated risk assessment tools for diverse populations.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A recent systematic review highlighted a half-dozen methods to improve antenatal STI screening in low- and middle-income countries in need of better options.